COMMUNIQUÉS West-GlobeNewswire

RadNet, Inc. Announces Date of its Third Quarter 2026 Financial Results Conference Call
29/10/2026
LOS ANGELES, Oct. 29, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
MINES and Associates Earns URAC Full Accreditation for Health Utilization Management
29/10/2026
The designation demonstrates a meaningful commitment to quality health care LITTLETON, Colo., Oct. 29, 2026 (GLOBE NEWSWIRE) -- MINES and Associates (MINES) is proud to announce that it has earned URAC Full [...]
Fortrea Reports Third Quarter 2026 Results
29/10/2026
Sustained commercial momentum, continued margin improvement, and targeted investments strengthen growth foundation Highlights For the three months ended September 30, 2026: Revenues of $691.5 million Book-to-bill ratio [...]
Biosplice Executives to Appear on Health Uncensored with Dr. Drew on Sunday, November 1
29/10/2026
Chief Executive Officer Erich Horsley and Chief Medical Officer Dr. Yusuf Yazici discuss the need for innovation in knee osteoarthritis and the development of lorecivivint, which is now under regulatory review in the [...]
Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
29/10/2026
Pivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday, November 14 ZUG, Switzerland, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company [...]
Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
29/10/2026
DEER PARK, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
29/10/2026
Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's disease Lecanemab presentations will [...]
Indivior Reports Third Quarter 2026 Financial Results
29/10/2026
Q3’26 Total Net Revenue of $ 356 Million, Up 13% YoY Record Quarterly Total SUBLOCADE® Net Revenue of $ 267 Million in Q3'26, Up 22% YoY Record Quarterly Net Income of $ 137 Million and Record Non-GAAP Net Income of $ [...]
Sironax Announces Three Abstracts on SARM1 Inhibitor SIR2501 Selected for Presentation at Neuroscience 2026
29/10/2026
Society for Neuroscience Annual Meeting, November 14-18, Washington, DC WALTHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Sironax, a global clinical-stage biotechnology company developing transformative therapies for [...]
Novastra Therapeutics to Present First-in-Human Data for OAP-101 in Checkpoint-Refractory Advanced Melanoma at SITC 2026 Annual Meeting
29/10/2026
Feasibility and innate-to-Th1 pharmacodynamics for candidate OAP-101, built on proprietary OmniAntigen™ Platform (OAP) OAP enables systematic immune reprogramming therapy (XIRT™) to overcome resistance of cold solid [...]
Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences
29/10/2026
BEDFORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation [...]
Tilray Brands Announces Next Phase of Beverage Transformation
29/10/2026
Successfully Completed Consolidation of U.S. Brewing Footprint from 10 Facilities to Six Identifying Further Opportunities to Reduce Complexity, Improve Brewery Utilization and Strengthen Margins Transformation [...]
Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations
29/10/2026
Appointments strengthen scientific leadership and operational capabilities as Opus advances its pipeline of gene therapies for inherited retinal diseases RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) -- [...]
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
29/10/2026
FOSTER CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis [...]
Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
29/10/2026
Over 2 million total VOQUEZNA® prescriptions filled through October 16, 2026 Q3 2026 net revenues of $84.7 million increased 71% vs. Q3 2025 and 14% vs. Q2 2026 Generated positive operating cash flow for the second [...]
Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)
29/10/2026
24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous mNSCLC, Consistent with Previously Reported Results IOV-LUN-202 Cohorts 1 and 2 Are Completing Enrollment and Support a Planned Supplemental Biologics [...]
Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance
29/10/2026
Company estimates approximately one million U.S. patients each month discontinue GLP-1 medications and face the risk of weight regain One-third of surveyed GLP-1 users expressed a preference for an endoscopic procedure [...]
BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
29/10/2026
—New data highlight BioCryst's commitment to advancing a portfolio of therapies for people living with HAE— RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) [...]
C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
29/10/2026
DEL Technology Integrating C4T’s Cereblon Library Can Rapidly Advance Projects Into Hit-To-Lead Stage WATERTOWN, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum